Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjd.15074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The treatment journey of children with moderate to severe atopic dermatitis in Türkiye: unmet needs.
Turk J Pediatr
July 2024
Department of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Türkiye.
Background: Atopic dermatitis (AD) substantially burdens individuals, families, and healthcare systems. We aimed to document the treatment journey of pediatric patients with moderate-to-severe AD in a referral center based in our country.
Methods: This retrospective study reviewed patients aged 1-18 years diagnosed with AD, seeking systemic treatment recommendations from the "pediatric allergy and dermatology multidisciplinary team meeting".
One-Bag 8-Step Ferric Carboxymaltose Desensitization Protocol for Patients with a History of Hypersensitivity Reactions to Iron Preparations.
Int Arch Allergy Immunol
May 2024
Department of Immunology and Allergy, Süreyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Introduction: Iron deficiency is the most common cause of anemia in both sexes, although it is more common in women. Intravenous (IV) iron replacement is preferred in patients who cannot tolerate oral treatment or when iron stores need to be replenished rapidly. In this study, we wanted to share the ferric carboxymaltose (FCM) desensitization protocol that we self-created and successfully applied.
View Article and Find Full Text PDFDiagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).
Allergol Select
October 2023
Department of Dermatology and Allergology, University Hospital Giessen, Justus Liebig University Gießen, Gießen, Germany.
Article Synopsis
- Hymenoptera venom (HV), injected by bees and wasps during stings, can cause allergic reactions in about 3% of people, leading to severe local or systemic allergic reactions in some cases.
- The guidelines suggest that while symptomatic therapy is needed after a severe local reaction, specific allergen immunotherapy isn't necessary unless severe reactions occur beyond the skin.
- Clinicians should assess patients for risk factors, measure tryptase levels if reactions are significant, and test for specific IgE antibodies to diagnose sensitization to Hymenoptera venom.
The effect of COVID-19 on patients recieving omalizumab treatment.
Rev Fr Allergol (2009)
March 2023
Division of Allergy Immunology, Department of Internal Medicine, Celal Bayar University, Manisa, Turkey.
Background And Aim: Although exposure during drug administration and susceptibility to coronavirus disease-19 (COVID-19) infection secondary to immunomodulatory effects constitute potential risks for patients with chronic spontaneous urticaria (CSU) or asthma on omalizumab (OMZ), there is a risk of loss of response following discontinuation of OMZ. There are few studies describing the clinical course of COVID-19 in patients receiving OMZ.
Materials And Methods: A total of 103 patients on OMZ were included in the study between February 2021 and January 2022.
The impact of home treatment and self-administration of omalizumab on chronic urticaria.
World Allergy Organ J
December 2022
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Background: Patients suffering from Chronic Spontaneous Urticaria (CSU) may be recalcitrant to treatment with high dose second-generation antihistamines. These patients are, according to international guidelines, eligible to treatment with omalizumab. Treatment with omalizumab has proven to be very effective for this group of patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!